Agonistic antibodies and/or RNA aptamers targeting receptors including 4-1BB, OX40, CD40, GITR, ICOS and CD28 are in pre-clinical development, and have shown anti-tumor activity in mouse models of cancer (Sanmamed et al., 2015). This evidence concerns the gene TNFRSF9 and cancer.